Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Gains from Investment Securities (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Gains from Investment Securities for 16 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 1399.09% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, up 260.95%, while the annual FY2025 figure was $3.3 million, 260.95% up from the prior year.
  • Gains from Investment Securities hit $3.3 million in Q4 2025 for Sangamo Therapeutics, up from -$45000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $7.4 million in Q4 2021 and bottomed at -$1.1 million in Q3 2023.
  • Average Gains from Investment Securities over 5 years is $878368.4, with a median of $203000.0 recorded in 2024.
  • Year-over-year, Gains from Investment Securities soared 2225.0% in 2022 and then plummeted 928.89% in 2023.
  • Sangamo Therapeutics' Gains from Investment Securities stood at $7.4 million in 2021, then crashed by 98.09% to $142000.0 in 2022, then soared by 688.03% to $1.1 million in 2023, then plummeted by 80.34% to $220000.0 in 2024, then soared by 1399.09% to $3.3 million in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $3.3 million, -$45000.0, and $10000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.